Simple Title
An Open-Label Study in Pediatric (<18 Years of Age), Severe Hemophilia A Participants (Coagulation Factor Activity <1%) With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing 12 Months of Historical Standard Treatment to Marstacimab Prophylaxis

Hemophilia A

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.


Hemophilia A, Hemophilia B

The disease, disorder, syndrome, illness, or injury that is being studied. On, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
The sex of people who may participate in a clinical trial (all, female, male). Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.
1 - 17 years
The age a person must be to participate in a clinical trial.
View more eligibility criteria on

Study Locations

Study Locations
No locations found.